title: Altered brain serotonin 5-HT1A receptor binding after recovery from anorexia nervosa measured by positron emission tomography and [carbonyl11C]WAY-100635.
abstract: BACKGROUND
  Previous studies have shown that women with anorexia nervosa (AN), when ill and after recovery, have alterations of serotonin (5-HT) neuronal activity and core eating disorder symptoms, such as anxiety.
  
  
  OBJECTIVE
  To further characterize the 5-HT system in AN, we investigated 5-HT1A receptor activity using positron emission tomography imaging because this receptor is implicated in anxiety and feeding behavior.
  
  
  METHODS
  To avoid the confounding effects of malnutrition, we studied 13 women who had recovered from restricting-type AN (mean age, 23.3 +/- 5.2 years) and 12 women who had recovered from bulimia-type AN (mean age, 28.6 +/- 7.3 years) (>1 year normal weight, regular menstrual cycles, no bingeing or purging). These subjects were compared with 18 healthy control women (mean age, 25.1 +/- 5.8 years). Intervention The 5-HT1A receptor binding was measured using positron emission tomography imaging and a specific 5-HT1A receptor antagonist, [carbonyl-11C]WAY-100635.
  
  
  METHODS
  Specific 5-HT1A receptor binding was assessed using the binding potential measure. Binding potential values were derived using both the Logan graphical method and compartmental modeling. The binding potential in a region of interest was calculated with the formula: binding potential = distribution volume of the region of interest minus distribution volume of the cerebellum.
  
  
  RESULTS
  Women recovered from bulimia-type AN had significantly (P<.05) increased [11C]WAY-100635 binding potential in cingulate, lateral and mesial temporal, lateral and medial orbital frontal, parietal, and prefrontal cortical regions and in the dorsal raphe compared with control women. No differences were found for women recovered from restricting-type AN relative to controls. For women recovered from restricting-type AN, the 5-HT1A postsynaptic receptor binding in mesial temporal and subgenual cingulate regions was positively correlated with harm avoidance.
  
  
  CONCLUSIONS
  We observed increased 5-HT1A receptor binding in women who had recovered from bulimia-type AN but not restricting-type AN. However, 5-HT1A receptor binding was associated with a measure of anxiety in women recovered from restricting-type AN. These data add to a growing body of evidence showing that altered serotonergic function and anxiety symptoms persist after recovery from AN. These psychobiological alterations may be trait related and may contribute to the pathogenesis of AN.
authors.affiliation: Department of Psychiatry, Western Psychiatric Institute and Clinic, Pittsburgh, PA 15213, USA.
authors.forename: Ursula F
authors.initials: UF
authors.lastname: Bailer
authors.forename: Guido K
authors.initials: GK
authors.lastname: Frank
authors.forename: Shannan E
authors.initials: SE
authors.lastname: Henry
authors.forename: Julie C
authors.initials: JC
authors.lastname: Price
authors.forename: Carolyn C
authors.initials: CC
authors.lastname: Meltzer
authors.forename: Lisa
authors.initials: L
authors.lastname: Weissfeld
authors.forename: Chester A
authors.initials: CA
authors.lastname: Mathis
authors.forename: Wayne C
authors.initials: WC
authors.lastname: Drevets
authors.forename: Angela
authors.initials: A
authors.lastname: Wagner
authors.forename: Jessica
authors.initials: J
authors.lastname: Hoge
authors.forename: Scott K
authors.initials: SK
authors.lastname: Ziolko
authors.forename: Claire W
authors.initials: CW
authors.lastname: McConaha
authors.forename: Walter H
authors.initials: WH
authors.lastname: Kaye
mesh_terms: D000328:Adult; D000367:Age Factors; D000856:Anorexia Nervosa / Q000000981:diagnostic imaging / Q000378:metabolism* / Q000523:psychology; D001835:Body Weight / Q000502:physiology; D001921:Brain / Q000000981:diagnostic imaging / Q000378:metabolism*; D002032:Bulimia / Q000000981:diagnostic imaging / Q000378:metabolism / Q000523:psychology; D002250:Carbon Radioisotopes; D002531:Cerebellum / Q000000981:diagnostic imaging / Q000378:metabolism; D002540:Cerebral Cortex / Q000000981:diagnostic imaging / Q000378:metabolism; D005260:Female; D006801:Humans; D009752:Nutritional Status / Q000502:physiology; D010879:Piperazines; D049268:Positron-Emission Tomography / Q000706:statistics & numerical data*; D011725:Pyridines; D044282:Receptor, Serotonin, 5-HT1A / Q000378:metabolism*; D058829:Serotonin 5-HT1 Receptor Antagonists; D012702:Serotonin Antagonists / Q000378:metabolism
chemical_list: D002250:Carbon Radioisotopes; D010879:Piperazines; D011725:Pyridines; D058829:Serotonin 5-HT1 Receptor Antagonists; D012702:Serotonin Antagonists; D044282:Receptor, Serotonin, 5-HT1A; C090413:N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide